Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Dec:35:20587384211006584.
doi: 10.1177/20587384211006584.

Off-label use of anti-IL-1 drugs in rheumatic diseases

Silvia Stefania  1 , Ripalta Colia  1 , Rotondo Cinzia  1 , Addolorata Corrado  1 , Francesco Paolo Cantatore  1
Affiliations

Off-label use of anti-IL-1 drugs in rheumatic diseases

Silvia Stefania et al. Int J Immunopathol Pharmacol. 2021 Jan-Dec.

Abstract

Interleukin-1 (IL-1) plays a key role in the pathogenesis of different rheumatic diseases. There are now several agents available on the market capable of blocking IL-1. The proven effectiveness and excellent safety of these drugs makes them a possible therapeutic option in the treatment of IL-1 driven diseases, when previous therapies are contraindicated or ineffective. This article discusses the European wide off-label use of these drugs for the treatment of rheumatic diseases.

Keywords: anakinra; anti IL-1; canakinumab; off-label use; rheumatic diseases.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Garlanda C, Dinarello CA, Mantovani A. (2013) The interleukin-1 family: Back to the future. Immunity 39(6): 1003–1018. - PMC - PubMed
    1. Marotto D, Batticciotto A, Ceribelli A, et al.. (2019) The journey of canakinumab; on- and off-label indications. Beyond Rheumatology 1(1): 22–30.
    1. Dinarello CA, Simon A, van der Meer JWM. (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery 11(8): 633–652. - PMC - PubMed
    1. Cvetkovic RS, Keating G. (2002) Anakinra. BioDrugs 16(4): 303–311. - PubMed
    1. Ruscitti P, Masedu F, Alvaro S, et al.. (2019) Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Medicine 16(9): 1–22. - PMC - PubMed

MeSH terms

LinkOut - more resources